#AACR26 How does it fare vs other adenosine studies? Oleclumab (anti-CD73) was studied in NeoCOAST-2 and showed pCR 20.3% (16% in PDL1 negative, 31% in PDL1 high). Should we target multiple enzymatic steps of adenosine pathway: combine anti-CD39 and anti-CD73 (IPH5301)? https://t.co/K6yk2hImgh